The number of women with heart disease who reach childbearing age in a good functional state increases continuously as advances in diagnosis and treatment improve overall health and prognosis. The cardiologist’s role is to give the woman an estimate of both maternal and fetal risk to allow her to make an informed decision about embarking on a pregnancy, and to provide appropriate antenatal care. There are only a few data about the natural history of anthracycline-induced cardiomyopathy during preg- nancy; we report our experience of a 29-year- old pregnant woman with a history of anthracycline-induced clinical heart failure.
References
[1]
Siu, S.C., Sermer, M., Colman, J.M., Alvarez, A.N., Mercier, L.-A., Morton, B.C., Kells, C.M., Bergin, M.L., Kiess, M.C., Marcotte, F., Taylor, D.A., Gordon, E.P., Spears, J.C., Tam, J.W., Amankwah, K.S., Smallhorn, J.F., Farine, D. and Sorensen, S. (2001) Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation, 104, 515-521.
doi:10.1161/hc3001.093437
[2]
Stangl, V., Schad, J., Gossing, G., Borges, A., Baumann, G., Stangl, K. (2008) Maternal heart disease and preg- nancy outcome: A single-centre experience. European Journal of Heart Failure, 10, 855-860.
doi:10.1016/j.ejheart.2008.07.017
Dalen, E.C.V, Pal, H.J.H.V.D., Bos, C.V.D., Kok, W.E.M., Caron, H.N. and Kremer, L.C.M.. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthra- cyclines (2006) European Journal of Cancer, 42, 2549- 2553. doi:10.1016/j.ejca.2006.04.014
